Bardoxolone methyl
未知生产厂商
RTA 402 inhibits the activity of nuclear factor kappa-B (NF-kB) activated by tumor necrosis factor (TNF) and other inflammatory agents in a variety of cancer cells. It is a novel targeted cancer therapy with a unique mechanism of action. It exploits fundamental physiological differences between cancerous and noncancerous cells by modulating oxidative stress response pathways. As a result, the drug is toxic to cancer cells but induces protective antioxidant and anti-inflammatory responses in normal cells.
Investigated for use/treatment in lymphoma (unspecified), multiple myeloma, and solid tumors.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
